Table 1.
Participant information for the four subject groups: Control subjects, subjects with cystic fibrosis and no intravenous (IV) aminoglycoside exposure (No IV-AG), subjects with cystic fibrosis and ≤ 40 weighted doses of aminoglycosides (Low IV-AG), and subjects with cystic fibrosis and > 40 weighted doses of aminoglycosides (High IV-AG).
| Variable | Controls | No IV-AG | Low IV-AG | High IV-AG |
|---|---|---|---|---|
| Individuals | 29 | 15 | 21 | 21 |
| Mean age, years (SD) | 28.3 (5.9) | 30.7 (10.0) | 27.5 (11.9) | 25.0 (5.0) |
| Percent male | 58.6% | 60.0% | 57.1% | 57.1% |
| Mean 4-freq PTA, a dB HL (SD) | 3.8 (3.2) | 7.2 (4.3) | 6.1 (4.4) | 7.5 (3.5) |
| Mean HFA, b dB HL (SD) | 5.4 (10.8) | 11.2 (15.9) | 7.3 (11.8) | 11.5 (10.7) |
| Mean 226-Hz static acoustic admittance in millimhos (min/max, SD) | 0.69 (0.3/1.5, 0.27) | 0.80 (0.3/1.6, 0.37) | 0.67 (0.3/1.3, 0.26) | 0.60 (0.2/1.5, 0.30) |
a
4-frequency pure-tone average (PTA) of thresholds at 0.5, 1.0, 2.0, and 4.0 kHz.
b
High-frequency average (HFA) of thresholds at 9.0, 10.0, 11.2, 12.5, 14.0, and 16.0 kHz.